NCT00295958View on ClinicalTrials.gov

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

July 31, 2008

Conditions
Melanoma (Skin)Non-melanomatous Skin Cancer
Interventions
BIOLOGICAL

LMB-2 immunotoxin

BIOLOGICAL

MART-1 antigen

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

Trial Locations (2)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

20892-1201

NCI - Surgery Branch, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00295958 - LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter